Participants will receive one of the two treatments for a defined period and will undergo two imaging procedures: a scan called 18F-FDG PET/CT, which shows how the heart uses sugar, and a scan named 99mTc-Tetrofosmin SPECT, which visualizes blood flow in the heart. These scans are performed at the beginning of the study and after the treatment phase to compare changes. Throughout the study, participants will attend regular visits for safety checks and to collect information about heart function and blood flow.

The purpose of the study is to demonstrate that tirzepatide is superior to placebo for glycemic control; participants are randomly assigned to receive either tirzepatide or a placebo, and neither the participants nor the study staff know which treatment is being given.

The study lasts about 40 weeks, during which the assigned injection is taken each week and regular clinic visits are made to check blood sugar, weight, and safety. Blood sugar control is measured with a test called Hemoglobin A1c (HbA1c), which shows the average level of glucose in the blood over the past two to three months. Obesity and overweight describe a condition where body weight is higher than what is considered healthy for a person’s height.

This clinical trial is focused on studying Type 1 Diabetes in adults who are also overweight or have obesity. The treatment being tested is called tirzepatide (also known by its code name LY3298176), which is given as a solution for injection using a pre-filled pen. The purpose of the study is to see if tirzepatide can help control blood sugar levels better than a placebo.

Participants in the study will receive either tirzepatide or a placebo once a week. The study will last for about 40 weeks. During this time, the effects of tirzepatide on blood sugar levels will be closely monitored. The study aims to determine if tirzepatide is more effective than a placebo in managing blood sugar levels in people with Type 1 Diabetes.

This study is important for understanding how tirzepatide can help people with Type 1 Diabetes who are also dealing with being overweight or obese. The results could provide valuable insights into new treatment options for better managing blood sugar levels in these individuals.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year, with regular clinic visits for injections and health checks. Blood samples will be taken to monitor liver enzymes (ALT and AST), a blood test called the ELF score that estimates liver scarring, and other measures such as cholesterol, blood sugar control (HbA1c), and body weight. Imaging tests, including a special ultrasound that measures liver stiffness (VCTE‑LSM), an MRI‑based scan (MRE), and an MRI that quantifies liver fat (MRI‑PDFF), will be performed at the start and at the end of the study to see how the liver is responding. Any side effects or abnormal lab results will be recorded throughout the study period.

The main goal of the research is to find out which individuals respond best to the treatment. Participants will receive the medication for about six months, with visits at the beginning and end of the period to collect information on weight, eating behavior, and other health measures.

Key outcomes include changes in BMI (a number that compares weight to height), changes in the Binge Eating Scale (a questionnaire that measures the severity of binge eating), as well as waist‑to‑hip ratio, body composition, appetite feelings, and various blood markers. Simple explanations are provided for any technical terms, such as BMI being a standard way doctors assess whether weight is in a healthy range.

The main goal of the study is to see whether a single dose of the medicine is safe and whether it can raise protein levels to a normal range, with some participants receiving a second dose later to assess longer‑term effects. Participants will receive the infusion, then attend regular visits over several months during which blood samples and simple health checks are performed.

Researchers will watch for any side effects, measure the amount of the protective protein in the blood, and test how well it works using a laboratory test called a elastase inhibition assay. They will also check lung function and liver health through routine exams and questionnaires to understand how the treatment impacts overall well‑being.

The investigational treatment is an injectable form of efimosfermin alfa, given under the skin (subcutaneous injection). Participants are randomly assigned to receive either the study drug or a placebo, and neither the participants nor the study staff know which one is given (double‑blind). The study lasts about one year, with regular clinic visits for injections and safety checks.

The main goal is to see whether the drug can improve liver health by reducing inflammation and decreasing scarring (fibrosis) compared with the placebo. Researchers will look at changes in the liver tissue, blood tests, and overall health over the treatment period.

The purpose of the study is to see if Orforglipron is as effective as Dapagliflozin in managing blood sugar levels. Participants will be randomly assigned to receive either Orforglipron or Dapagliflozin, both taken as capsules by mouth once a day. Some participants may receive a placebo, which looks like the real medication but does not contain the active ingredient. The study will monitor changes in blood sugar levels over time to assess the effectiveness of the treatments.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the medication. The study aims to provide valuable information on how well Orforglipron works compared to Dapagliflozin in people with Type 2 Diabetes who are already taking Metformin. This research could help improve treatment options for managing blood sugar levels in individuals with this condition.